Skip to main content

Glaxo to Pursue Work of Biogen Lab

ZURICH—Officials at Glaxo, the British pharmaceutical giant that has agreed to purchase the Geneva research laboratory of Biogen N.Y., have promised that the facility will retain a degree of autonomy as an intemational center of excellence in biotechnology. John Barr, a spokesman for Glaxo, said that the laboratory will be integrated into the company’s general research program and renamed the Glaxo Institute for Molecular Biology. The new director of research will be Allan Will

Written byMarc Nicholls
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00

ZURICH—Officials at Glaxo, the British pharmaceutical giant that has agreed to purchase the Geneva research laboratory of Biogen N.Y., have promised that the facility will retain a degree of autonomy as an intemational center of excellence in biotechnology.

John Barr, a spokesman for Glaxo, said that the laboratory will be integrated into the company’s general research program and renamed the Glaxo Institute for Molecular Biology. The new director of research will be Allan Williamson, who previously headed Glaxo’s mammalian research interests in the United Kingdom. Glaxo will assume responsibility for work on the immune modulators interleukin-2 and granulocyte-macrophage colony stimulating factor, both now in clinical trials.

The July 28 announcement of the sale of the Geneva facility was totally unexpected. Officials of Biogen, based in Cambridge, Mass., had been holding discussions for several months with a number of firms in an attempt to stanch losses that topped $20 million last ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter
Optimizing SV-AUC for Peptide Therapeutic Analysis

Optimizing SV-AUC for Peptide Therapeutic Analysis

​Beckman Coulter
Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen